Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD9-blocking antibody
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD9-blocking antibodies are monoclonal antibodies designed to target and inhibit CD9 (tetraspanin-29), a cell-surface glycoprotein involved in cell adhesion, migration, and tumor progression. In hematological malignancies, CD9 is upregulated via the STAT5B pathway in leukemic stem cells (LSCs), promoting self-renewal and survival. Blocking CD9 disrupts these pathways, inducing differentiation and apoptosis in STAT5-dependent leukemia cells. Additionally, CD9-blocking antibodies are being investigated for their potential to inhibit metastasis and modulate immune cell infiltration in solid tumors.
- Other names
- CD9 antibodyCD-9 antibodyCD 9 antibodyCD9-blocking mAbCD-9-blocking mAbCD 9-blocking mAbanti-CD9 antibodyanti-CD-9 antibodyanti-CD 9 antibodyanti-CD9 monoclonal antibodyanti-CD-9 monoclonal antibodyanti-CD 9 monoclonal antibody
02
Targets
CD9 (CD9 antigen)
Beyond the preview
Go deeper on CD9-blocking antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD9-blocking antibody.